The OncoAlert 🚨 coverage of #ESMOBreast24 is coming soon 📨📨.

To get it for free in your inbox, register at:
Oncoalert360.com or oncoalert.m-pages.com/nhMpwe/oncoale……

The OncoAlert NEWSLETTER is OUT! Don't miss it!

Covering May 9-16 , 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……

1/2 Excited to launch this pan🇨🇦 ph. 2 RCT of FMT+ICI in melanoma with the CCTG J. Lenehan Janet Dancey Saman Maleki, PhD. Thanks to the Canadian Cancer Society Weston Family Foundation we will understand the mechanism of FMT to unlock the next gen of microbiome therapeutics Bertrand Routy MD,PhD

D3S-001, a next generation GDP-bound #KRAS G12C inhibitor demonstrates robust preclinical and clinical activity.
✅Rapid target engagement
✅Active KRAS G12C depletion at nanomolar concentrations
✅Kinetics nearly unaffected in presence of growth factors (e.g. EGF/HGF) (vs

Dear Colleagues,
TWO WEEKS until #ASCO24 🌐
WE ARE READY
WE ARE OncoAlert 🚨

#OncoAlertAF
Dra. María Natalia Gandur Quiroga 🇦🇷
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz 🇺🇸
Hidehito HORINOUCHI 🇯🇵
Fadi Haddad, MD 🇺🇸
Dr. Iván R. González 🇲🇽

The OncoAlert🚨ROUND UP
Covering May 2-8, 2024

👇👇👇

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Comprehensive mutational scanning of #EGFR reveals TKI sensitivities of extracellular domain mutants. shorturl.at/lrI45

🧬Multiple EGFR extracellular domain variants, not associated with approved targeted therapies, were sensitive to afatinib and dacomitinib in vitro.

The 🚨 OncoAlert newsletter is out!! Covering May 2-8, 2024. #OncoAlertAF
👇
REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale……

The Lancet Commission highlights the urgent need to address the projected doubling of global #ProstateCancer cases by 2040

Doing so by:
✅Early diagnosis strategies
✅Equitable access to care
✅increased research focus on ethnic disparities and treatment distribution in LMICs

DESTINY-PanTumor01 :Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations

#LungCancer 🫁
OncoAlert 🚨

Great overview of resistance mechanisms to #KRAS inhibitors in #NSCLC at #RomeLung24 by AmbrogioLab. Different therapeutic vulnerabilities depending on whether resistance is intrinsic, acquired, or adaptive.

DESTINY-PanTumor01
Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations

✅Demonstrating significant anti-tumor activity and durable responses, alongside manageable safety profiles

➡️suggesting potential

Had a great time and insightful discussions at #RomeLung24 reviewing biomarkers for #ICI efficacy in #NSCLC . w/ a stellar faculty Jordi Remon Solange Peters Francesco Christian Rolfo, Tony Mok Stephen V Liu, MD, Fred R. Hirsch Federico Cappuzzo Roberto Ferrara Benjamin Besse &

Important effort to out in Nature Communications characterizing FAK-YAP signaling as mediator of residual disease during targeted therapies in #NSCLC .

✅FAK-YAP inhibition + targeted therapy 💊 combo suppresses residual drug-tolerant cells.
🚨🚨OncoAlert #LCSM
shorturl.at/aexAO

The new OncoAlert 🚨 newsletter is OUT!
Don’t miss it! And if you don’t have a subscription, register at oncoalert.m-pages.com/nhMpwe/oncoale… for the latest in oncology.

Just out on Journal for ImmunoTherapy of Cancer 🚨
The Society for Immunotherapy🧪 of Cancer's expert panel devised tailored clinical trial designs to maximize the efficacy of intratumoral immunotherapies across various stages of #Cancer

✅addressing key considerations such as patient selection,

Gefitinib + chemotherapy combo continues to show ⬆️PFS & OS at 5y of follow-up vs gefitinib monotherapy in #EGFR + #NSCLC .
5-year OS: 13% vs 4.4% (HR, 0.58). 5-year PFS: 6.7% vs 1.7% (HR, 0.53). Implications for countries with limited access to 3rd gen TKIs 🚨🚨OncoAlert #LCSM

Dear Colleagues,
One Month until #ASCO24 🌐
WE ARE READY
WE ARE OncoAlert 🚨

#OncoAlertAF
Dra. María Natalia Gandur Quiroga 🇦🇷
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz 🇺🇸
Hidehito HORINOUCHI 🇯🇵
Fadi Haddad, MD 🇺🇸
Dr. Iván R. González 🇲🇽

If you are attending #ASCO24 don’t forget to register to the 🚨 OncoAlert 5K walk/run. June 1st, 7 AM. Start Hyatt Regency at McCormick Place, Chicago!
⬇️⬇️⬇️